Heat-activated intravenous liposomal doxorubicin combined with mitomycin C hyperthermic intravesical chemotherapy (HIVEC) for treatment of bladder cancer.

PURPOSE: To evaluate the safety and pharmacokinetics of lyso-thermosensitive liposomal doxorubicin (LTLD, ThermoDox®) combined with mitomycin C (MMC) hyperthermic intravesical chemotherapy (HIVEC) as a potential treatment for non-muscle invasive bladder cancer.

MATERIALS AND

METHODS

Four healthy swine received a 30-minute intravenous infusion of LTLD in combination with HIVEC, consisting of one hour of warm MMC bladder recirculation. Full-thickness bladder wall specimens were surgically resected within 30 min of HIVEC completion for histologic analysis and assessment of doxorubicin (DOX) intrinsic fluorescence in cross sections. DOX and MMC concentrations were also measured in bladder specimens and in serial blood samples up to 4 h by LC/MS. Swine were monitored for 28 days for signs of toxicity and were weighed weekly. Complete blood counts were performed at 4 h and 28 days. Cystoscopy was performed at 28 days, and bladder tissue was collected for histology and quantification of drug concentrations.

RESULTS

Mean DOX concentration in the bladder wall 30 min after treatment was 13.6 ± 4.67 µg/g, and DOX fluorescence was visible in all layers. Plasma DOX Cmax and AUC0-∞ were 16.4 ± 3.46 µg/mL and 23.2 ± 5.50 µg/mL · h, respectively. MMC was not detected in the bladder wall or blood above the lower limit of detection (20 ng/mL). The treatment was well tolerated, with no treatment-related adverse events and no weight loss during the 28-day observation. On day 28, cystoscopy demonstrated normal-appearing bladder lumen, and some vacuolated cells were observed on bladder wall histology.

CONCLUSIONS

Intravenous LTLD combined with MMC HIVEC was feasible and well tolerated in swine.